Literature DB >> 15868957

Structure-activity relationships of a new class of aromatic bisphosphonates that inhibit tumor cell proliferation in vitro.

Erwann Guenin1, Dominique Ledoux, Olivier Oudar, Marc Lecouvey, Michel Kraemer.   

Abstract

We previously reported a simple and efficient one-pot procedure for synthesis of 1-hydroxymethylene-1,1-bisphosphonic acids (HMBP). According to this method, we synthesized a series of new aromatic HMBP and investigated structure-activity relationships by evaluating their anti-proliferative activity against A431 human tumor cell line. Our results showed that the introduction of an extra methylene group in a pyridyl-containing R2 side chain increased 100-fold the anti-proliferative activity of the HMBP. In contrast, this chemical modification did not modify the anti-proliferative activity of compounds substituted with a phenyl-containing R2 side chain. Para-substitution of the phenyl ring with various groups markedly influenced the HMBP activity, the order of potency (bromine > chlorine > fluorine = none) closely matching the atomic volume of the substituted group. Moreover, changes in the substitution position of the bromine group also affected the anti-proliferative activity, the more potent activity being obtained with para-substitution of the phenyl ring. In conclusion, this structure-activity study led us to identify the new aromatic HMBP [(4-Bromo-phenyl)-hydroxy-phosphono-methyl]-phosphonic acid as a potent in vitro anti-proliferative molecule against tumor cell lines (IC50 value of 9.5 x 10(-5) M). Interestingly, this compound can be further easily esterified on its phosphonic acid functions according to our chemical method and, thus, represents a potential candidate for the development of new esterified HMBP with enhanced pharmacokinetics.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15868957

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  5 in total

1.  Models for anti-tumor activity of bisphosphonates using refined topochemical descriptors.

Authors:  Rakesh K Goyal; G Singh; A K Madan
Journal:  Naturwissenschaften       Date:  2011-09-04

2.  Potentiating bisphosphonate-based coordination complexes to treat osteolytic metastases.

Authors:  Gabriel Quiñones Vélez; Lesly Carmona-Sarabia; Waldemar A Rodríguez-Silva; Alondra A Rivera Raíces; Lorraine Feliciano Cruz; Tony Hu; Esther Peterson; Vilmalí López-Mejías
Journal:  J Mater Chem B       Date:  2020-03-11       Impact factor: 6.331

3.  New symmetrically esterified m-bromobenzyl non-aminobisphosphonates inhibited breast cancer growth and metastases.

Authors:  Mohamed Abdelkarim; Erwann Guenin; Odile Sainte-Catherine; Nadejda Vintonenko; Nicole Peyri; Gerard Yves Perret; Michel Crepin; Abdel-Majid Khatib; Marc Lecouvey; Mélanie Di Benedetto
Journal:  PLoS One       Date:  2009-03-05       Impact factor: 3.240

4.  Towards potential nanoparticle contrast agents: Synthesis of new functionalized PEG bisphosphonates.

Authors:  Souad Kachbi-Khelfallah; Maelle Monteil; Margery Cortes-Clerget; Evelyne Migianu-Griffoni; Jean-Luc Pirat; Olivier Gager; Julia Deschamp; Marc Lecouvey
Journal:  Beilstein J Org Chem       Date:  2016-07-04       Impact factor: 2.883

5.  High affinity zoledronate-based metal complex nanocrystals to potentially treat osteolytic metastases.

Authors:  Gabriel Quiñones Vélez; Lesly Carmona-Sarabia; Alondra A Rivera Raíces; Tony Hu; Esther A Peterson-Peguero; Vilmalí López-Mejías
Journal:  Mater Adv       Date:  2022-02-23
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.